Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) is a major global health concern.
• The PI3K/AKT/mTOR signaling pathway plays a critical role in HCC development and progression.
• Targeting this pathway is a promising therapeutic strategy for HCC.

Purpose of the Study:

• To investigate the effect of sorafenib on the PI3K/AKT/mTOR signaling pathway.
• To elucidate the mechanism by which sorafenib exerts its anti-cancer effects in HCC.

Main Methods:

• Human SMMC-7721 hepatic carcinoma cells were utilized for in vitro experiments.
• Cells were treated with sorafenib (4 μmol/L) for varying durations (0-48 hours).
• Changes in PI3K, mTOR, and AKT protein and mRNA expression levels were assessed.

Main Results:

• Sorafenib treatment led to a significant decrease in the expression of PI3K, mTOR, and AKT.
• The downregulation was observed at both protein and mRNA levels.
• These findings indicate sorafenib's inhibitory effect on the PI3K/AKT/mTOR pathway.

Conclusions:

• Sorafenib demonstrates anti-cancer activity in HCC by inhibiting the PI3K/AKT/mTOR signaling pathway.
• Downregulation of this pathway is a key mechanism for sorafenib's therapeutic effect in liver cancer.
• This study provides a molecular basis for the use of sorafenib in HCC treatment.